Please assess the completion status of the following clinical trial:

Trial Title: Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients with genetically confirmed Rett Syndrome (RTT)~* Age: 10 or more years old. Selection of the age is based on the available evidence of the safety of Glatiramer Acetate (GA) in this group, and the relative homogeneity/stability of the phenotype, which is not expected to spontaneously change within a 6 month period at this age~* Ambulatory (with our without support)~Exclusion Criteria:~* Prolonged Qtc (obtained within 30 days prior to enrollment)~* Presence of co morbid non-Rett related disease~* Presence of immunodeficiency requiring intravenous immunoglobulin 3 (IVIG 3) months prior to enrollment~* Allergy/sensitivity to GA or mannitol~* Inability or unwillingness of legal guardians to give written informed consent

- Gender: FEMALE
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Copaxone (Type: EXPERIMENTAL): Dose escalation:~Study drug will be administered once a week for 4 weeks, twice a week for 4 weeks and daily for 24 weeks. Drug is administered as a subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).